Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
'Afgeslankte' versie van COBRA meest kosteneffectief bij vroege RA
mei 2020 | RA